Contact Us   |   Print Page   |   Sign In   |   Join
Bioarbor December 2018
Tell a Friend About This EventTell a Friend

The Good, The Bad, and The Ugly: Serial CEO's Tell Their Stories

When: Wednesday, December 12, 2018
Where: Ann Arbor SPARK Central Innovation Center
330 E. Liberty Street
Ann Arbor, Michigan  48104
United States
Contact: Alisha Brown

Online registration is closed.
« Go to Upcoming Event List  






The Good, The Bad, and The Ugly.


CEO's, CFO's and other senior leadership are often brought in, at best, when an organization is looking for new direction, and, at worst, when the organization is in crisis. Their essential function is to look for opportunities and make the tough choices necessary to move forward. That process can get them branded as the enemy and make real change more difficult. Listen as a group of experienced senior leaders, who have worked with many organizations, discuss the good--what works, the bad--common mistakes, and the ugly--the hard solutions that challenge leadership.




Stephen Benoit, President & CEO, MDI Therapeutics

Stephen Benoit brings to MDI Therapeutics broad experience in VC-backed start-ups and small and large-cap public companies in the pharmaceuticals, food & agriculture biotechnology, food safety training and education, consumer packaged foods, and specialty ingredients industries. Prior to joining MDI Therapeutics, Stephen was CEO of Metabolic Solutions Development Company (MSDC), a clinical-stage developer of small molecule therapeutics to treat diseases associated with metabolic dysfunction. During his tenure, MSDC raised more than $70 million from top-tier and regional VC's, family offices, angels, and high net worth individuals, including a $40 million financing for a new spinout company (Cirius Therapeutics), which was led by Frazier Healthcare Partners, Novo Ventures. He continues to serve on the MSDC Board of Managers, and is a consultant to Cirius Therapeutics.















Julia Owens, Ph.D., President & CEO, Millendo 

Dr. Julia C. Owens has an extensive background in venture-backed biopharmaceutical companies and particular expertise in pharmaceutical company transactions. Prior to co-founding Millendo, she served as senior vice president, corporate development and strategy at Lycera Corp., where she led the partnering process that led to Lycera's major research partnership with Merck & Co. She also acquired a new platform discovery program for the company and negotiated its partnership with the University of Michigan, moving the company to the North Campus Research Complex. Prior to Lycera, Dr. Owens served as head of business development at QuatRx Pharmaceuticals for six years. There, she established several key partnerships, including one with Shionogi for the approved drug, Osphena®. Earlier in her career, Dr. Owens worked at Tularik Inc. (now Amgen San Francisco) in business development for five years, where she led partnering for the oncology and immunology areas, as well as chaired the company's technology acquisition efforts.


Sundu Brahmasandra, President & COO, NeuMoDx Molecular

Sundu serves as the President of NeuMoDx Molecular. Most recently, he served as the President of Life Magnetics, Inc. a spin-out from the University of Michigan developing a novel, non-microscope based platform for real-time monitoring of cell growth, death and other binding events. Prior to Life Magnetics, Sundu served as a VP of R&D/Assay Development in the Infectious Disease division at BD Diagnostics. Prior to BD, Sundu was Co-Founder and V.P. Product Development of HandyLab, Inc., where he led the development & validation of the Jaguar molecular diagnostic platform as well as proprietary nucleic acid preparation technologies and a multitude of real-time PCR assays spanning molecular diagnostics, food-borne pathogen detection, GMO testing and other applications. HandyLab was acquired by BD in Nov 2009 for more than $275 million. Sundu received his BS from the Indian Institute of Technology, Chennai and a PhD in Chemical Engineering from the University of Michigan in 2001.
















Stephen Radundalo, Ph.D., President & CEO, MichBio


Dr. Rapundalo, has broad experience in the life sciences, with an extensive background in pharmaceutical research and development. Prior to joining MichBio in April 2006, he spent almost 20 years as a senior research scientist, project manager, and group leader with Parke-Davis Pharmaceutical Research and then Pfizer, Inc., primarily in the area of cardiovascular drug discovery. 
Dr. Rapundalo also led a global interdisciplinary team that developed a strategic, operational and organizational change management program to improve Pfizer's worldwide R&D business processes. He has a strong background in innovation and is an internationally recognized expert in a number of technology areas including high-throughput screening and proteomics, among others. 




BioArbor is generously sponsored by:




Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal